{"resourceType":"ResearchStudy","phase":{"coding":[{"code":"phase-3","display":"Phase 3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","version":"1.0.0"}]},"identifier":[{"assigner":{"display":"Reference to primary assigner","reference":"Organization/ctis","type":"Organization"},"use":"official","value":"2022-500014-26-00"}],"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date","valueInstant":"2023-04-12T00:00:00.000Z"},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area","valueString":"[Traduction locale] Diseases [C] - Neoplasms [C04]"},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period","valuePeriod":{"start":"2022-06-30T00:00:00.000Z"}},{"extension":[{"url":"name","valueString":"F. Hoffmann-La Roche AG"},{"url":"role","valueCodeableConcept":{"coding":[{"code":"lead-sponsor","display":"lead-sponsor","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system","version":"0.3.0"}]}},{"url":"party","valueReference":{"display":"Reference to primary sponsor","reference":"Organization/2022-500014-26-00-primary-sponsor","type":"Organization"}}],"url":"http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.associatedParty"}],"title":"[Traduction locale] A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","enrollment":[{"display":"Reference to group detailing study characteristics","reference":"Group/2022-500014-26-00-enrollment-group","type":"Group"}],"condition":[{"id":"disease-condition-2022-500014-26-00","text":"[Traduction locale] Locally-Advanced or Metastatic breast cancer (MBC)"},{"id":"meddra-condition-2022-500014-26-00-10070575","coding":[{"code":"10070575","display":"Cancer du sein à récepteurs aux oestrogènes positifs","system":"https://www.meddra.org","version":"3.0.0"}]},{"id":"meddra-condition-2022-500014-26-00-10065430","coding":[{"code":"10065430","display":"Cancer du sein HER2 positif","system":"https://www.meddra.org","version":"3.0.0"}]}],"site":[{"display":"Reference to site","reference":"Location/2022-500014-26-00-0-site","type":"Location"}],"meta":{"lastUpdated":"2023-04-12T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"contact":[{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name","valueHumanName":{"family":"Trial Information Support Line-TISL, Switzerland","given":["Head of EU"],"use":"official"}}],"telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]},{"extension":[{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name","valueHumanName":{"given":[],"use":"official"}},{"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type","valueCodeableConcept":{"coding":[{"code":"PUB","display":"Publique / Public","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","version":"0.3.0"}]}}],"telecom":[{"system":"phone","use":"work"},{"system":"email","use":"work"}]}],"location":[{"coding":[{"code":"BE","display":"Belgium","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"DE","display":"Germany","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"ES","display":"Spain","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"FR","display":"France","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"HU","display":"Hungary","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"IT","display":"Italy","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"PL","display":"Poland","system":"urn:iso:std:iso:3166","version":"4.0.1"}]},{"coding":[{"code":"PT","display":"Portugal","system":"urn:iso:std:iso:3166","version":"4.0.1"}]}],"id":"2022-500014-26-00","text":{"div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>Données reçues avant modélisation FHIR</h2><ul><li> reglementation_code: REG536 </li><li> precision_reglementation: un essai clinique (CTIS) </li><li> etat: EN_COURS </li><li> organisme_nom: F. Hoffmann-La Roche AG </li><li> organisme_adresse: Grenzacherstrasse 124 </li><li> organisme_code_postal: 4058 </li><li> organisme_pays: Switzerland </li><li> organisme_ville: Basel Town </li><li> contact_nom: Trial Information Support Line-TISL, Switzerland </li><li> contact_prenom: Head of EU </li><li> contact_telephone: 0041616881111 </li><li> contact_courriel: global.rochegenentechtrials@roche.com </li><li> sites: Organisme: Donnée non disponible - Adresse: Avenue Eugene Avinee - Ville: Lille - Titre: Dr. - Nom: Aumar - Prenom: Madeleine - Service: Gastroenterology Hepatology and Nutrition Unit Paediatric clinic, Child Unit </li><li> numero_primaire: 2022-500014-26-00 </li><li> titre: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER </li><li> phase_recherche: Phase III </li><li> domaine_therapeutique: Diseases [C] - Neoplasms [C04] </li><li> pathologies_maladies_rares: Locally-Advanced or Metastatic breast cancer (MBC) </li><li> informations_meddra: 10070575,10065430 </li><li> taille_etude: 21 </li><li> tranches_age: 65+ years,18-64 years </li><li> sexe: Male,Female </li><li> groupes_sujet: Données non disponible </li><li> population_recrutement: Women of child bearing potential not using contraception,Women of child bearing potential using contraception </li><li> date_debut_recrutement: 2022-06-30T00:00:00.000Z </li><li> historique: 2023-03-16:En cours </li><li> dates_avis_favorable_ms_mns: 22.00800.000094-SM-1:2022-11-07, 22.00800.000094-SM-2:2023-04-12 </li><li> pays_concernes: BE,DE,ES,FR,HU,IT,PL,PT </li><li> date_theorique_maximale_autorisation_cpp: 2023-03-15 </li><li> contact_public: Nom: null - Prenom: null Courriel: null Tel: null </li><li> criteres_eligibilite: Titre: null - Type: null,Titre: TEST INCLUSION - Type: INCLUSION,Titre: TEST EXCLUSION - Type: EXCLUSION </li><li> criteres_jugement: Titre: null - Type: null,Titre: TEST PRINCIPAL - Type: PRINCIPAL,Titre: TEST SECONDAIRE - Type: SECONDAIRE </li><li> objectifs: null </li><li> resume: null </li><li> statut_recrutement: Recrutement en attente </li><li> date_fin_recrutement: null </li></ul></div>","status":"extensions"},"category":[{"coding":[{"code":"REG536","display":"REG536 (CTIS)","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system","version":"0.3.0"}]},{"coding":[{"code":"study-ctis","display":"un essai clinique (CTIS)","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system","version":"0.3.0"}]}],"status":"active"}